Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,827 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03173248 | Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation(AGILE) | active not recruiting | Phase 3 | 146 | Institut de Recherches Internationales ServierOTHER | 20 | Jun 29, 2026 | clinicaltrials |
| NCT04248829 | Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301) | completed | Phase 3 | 393 | Yuhan CorporationINDUSTRY |
| 13 |
| Jun 29, 2026 |
| clinicaltrials |
| NCT05376644 | Molecular Imaging of HER2 Expression in HER2-positive Breast Cancer Using 99mTc-ADAPT6 vs 99mTc-DARPinG3 | completed | N/A | 15 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT02393859 | Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL) | completed | Phase 3 | 111 | AmgenINDUSTRY | 24 | Jun 26, 2026 | clinicaltrials |
| NCT04292626 | Molecular Imaging of Lymphoma Using Labeled Technetium-99m 1-Thio-D-Glucose | completed | Phase 1 | 16 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT05203497 | Molecular Imaging of HER2 Expression in Breast Cancer Using 99mTc-ZHER2 | completed | Phase 1 | 30 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT05940298 | Molecular Imaging of Gastrin Releasing Peptide Receptors Using Labeled Technetium-99m DB8 | completed | Phase 1 | 10 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT06641219 | Clinical Evaluation of [177Lu]Lu-BQ7876 for Targeting of Prostate-Specific Membrane Antigen | completed | Phase 1 | 7 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT07146113 | Treatment Approaches and Biomarkers PRevalence In de Novo MEtastatic Hormone-sensitive Prostate Cancer in Russian Federation(PRIME) | suspended | — | 400 | AstraZenecaINDUSTRY | 1 | Jun 26, 2026 | clinicaltrials |
| NCT03088540 | Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 3 | 712 | Regeneron PharmaceuticalsINDUSTRY | 24 | Jun 25, 2026 | clinicaltrials |
| NCT03872401 | Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke(VESALIUS-CV) | completed | Phase 3 | 12,301 | AmgenINDUSTRY | 33 | Jun 25, 2026 | clinicaltrials |
| NCT04529772 | A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)(ESCALADE) | active not recruiting | Phase 3 | 611 | Acerta Pharma BVINDUSTRY | 23 | Jun 25, 2026 | clinicaltrials |
| NCT07457541 | Molecular Imaging of Fibroblast Activation Protein Expression Using Labeled Technetium-99m HYNIC-FAPI | active not recruiting | Phase 1 | 15 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT03991260 | 99mTc-ADAPT6-based HER2 Imaging in Breast Cancer(99mTc-ADAPT6) | completed | — | 16 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT04277338 | Molecular Imaging of HER2 Expression in Breast Cancer Using 99mTc-HE3-G3(HE3-G3) | completed | Phase 1 | 30 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT04288518 | Molecular Imaging of Brain Tumors Using Labeled Technetium-99m 1-Thio-D-Glucose. | completed | Phase 1 / Phase 2 | 16 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT04746638 | Molecular Imaging of Gastrin Releasing Peptide Receptors Using Labeled Technetium-99m RM26 | completed | Phase 1 | 10 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT04817501 | Phenotypic Spectrum of CTCs in Tumors of the Female Reproductive System(CTCs) | completed | — | 150 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT05412446 | 99mTc-ADAPT6 SPECT-based Non-invasive Quantification of HER2-expression in Breast Cancer With Metastatic Lymph Nodes(99mTc-ADAPT6) | completed | Phase 2 | 30 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT05412459 | 99mTc-DARPinG3-based HER2 Expression Molecular Imaging in HER2-positive Breast Cancer During Chemo+Targeted Therapy | completed | — | 15 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT05620472 | Molecular Imaging of EpCAM Receptors Using [99mTc]Tc(CO)3-(HE)3-Ec1 | completed | Phase 1 | 10 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT05695859 | 99mTc-DARPinG3 SPECT/CT for Non-invasive HER2-AX in Breast Cancer With Metastatic Lymph Nodes Before Targeted Therapy | completed | — | 24 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT05923177 | Molecular Imaging of HER2 Expression in Breast Cancer Using [123I] I-(HE)3-G3 | completed | Phase 1 | 10 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT05923268 | Molecular Imaging of HER2 Expression in Breast Cancer Using [99mTc]Tc-G3-(G3S)3C Before Chemo/Targeted Therapy | completed | N/A | 10 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT06101927 | Molecular Imaging of Prostate-Specific Membrane Antigen Using Labeled Technetium-99m BQ0413 | completed | Phase 1 | 10 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT06386653 | Molecular Imaging of EpCAM Receptors Using [123I]I-DARPIN-Ec1 | completed | Phase 1 | 10 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07275463 | [99mTc]Tc-DB8 Accumulation in Primary Tumor in Breast Cancer With Positive and Negative Estrogen Receptor Expression | enrolling by invitation | Phase 2 | 40 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07292571 | Evaluation of Different Types of HER2 Expression in Breast Cancer Using [99mTc]Tc -ZHER2:4107 | enrolling by invitation | Phase 2 | 50 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07475390 | 99mTc-1-thio-D-glucose SPECT/CT Versus 18F-Fluoroethyl-l-tyrosine PET/CT in Brain Tumor Imaging | active not recruiting | N/A | 40 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT00196742 | Fabry Disease Registry & Pregnancy Sub-registry | recruiting | — | 9,000 | Genzyme, a Sanofi CompanyINDUSTRY | 44 | Jun 23, 2026 | clinicaltrials |
| NCT05059522 | Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing | active not recruiting | Phase 3 | 77 | PfizerINDUSTRY | 19 | Jun 22, 2026 | clinicaltrials |
| NCT04102098 | A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation(IMbrave050) | completed | Phase 3 | 668 | Hoffmann-La RocheINDUSTRY | 26 | Jun 18, 2026 | clinicaltrials |
| NCT04475939 | Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer(ZEAL-1L) | completed | Phase 3 | 666 | GlaxoSmithKlineINDUSTRY | 27 | Jun 18, 2026 | clinicaltrials |
| NCT04623775 | A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 468 | Bristol-Myers SquibbINDUSTRY | 19 | Jun 18, 2026 | clinicaltrials |
| NCT06104566 | Global Trial in APG2575 for Patients With CLL/SLL | recruiting | Phase 3 | 400 | Ascentage Pharma Group Inc.INDUSTRY | 19 | Jun 18, 2026 | clinicaltrials |
| NCT07658170 | Evaluation of the Efficacy and Safety of Using Platelet-rich Fibrin (PRF)-Based Lipobolus for the Immediate Reconstruction of Defects After Breast-conserving Resection for Breast Cancer (Minimally Invasive Primary Immediate Grafting)(MINIPIG) | recruiting | N/A | 30 | The Leningrad Regional Clinical HospitalOTHER_GOV | 1 | Jun 18, 2026 | clinicaltrials |
| NCT03631199 | Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects(CANOPY-1) | terminated | Phase 3 | 673 | Novartis PharmaceuticalsINDUSTRY | 41 | Jun 17, 2026 | clinicaltrials |
| NCT04512235 | A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES) | active not recruiting | Phase 3 | 281 | Alexion Pharmaceuticals, Inc.INDUSTRY | 19 | Jun 17, 2026 | clinicaltrials |
| NCT07143604 | A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2(GAMBIT) | active not recruiting | Phase 2 | 33 | AstraZenecaINDUSTRY | 1 | Jun 17, 2026 | clinicaltrials |
| NCT04941768 | An Observational Study to Evaluate the Efficacy and Safety of Avelumab + Axitinib Combination in Participants With aRCC (AVION) | completed | — | 105 | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyINDUSTRY | 4 | Jun 16, 2026 | clinicaltrials |
| NCT04181788 | Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies | completed | Phase 1 / Phase 2 | 155 | PfizerINDUSTRY | 6 | Jun 15, 2026 | clinicaltrials |
| NCT06245837 | Treatment and Biomarker Testing Patterns,Treatment Outcomes in a/m NSCLC With and Without Actionable Genomic Alterations | active not recruiting | — | 1,500 | AstraZenecaINDUSTRY | 1 | Jun 15, 2026 | clinicaltrials |
| NCT04421963 | Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib(ROSY-O) | active not recruiting | Phase 3 | 185 | AstraZenecaINDUSTRY | 23 | Jun 12, 2026 | clinicaltrials |
| NCT04484623 | Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma(DREAMM 8) | active not recruiting | Phase 3 | 302 | GlaxoSmithKlineINDUSTRY | 18 | Jun 12, 2026 | clinicaltrials |
| NCT02993523 | A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy(Viale-a) | active not recruiting | Phase 3 | 443 | AbbVieINDUSTRY | 29 | Jun 11, 2026 | clinicaltrials |
| NCT03003962 | Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL) | active not recruiting | Phase 3 | 669 | AstraZenecaINDUSTRY | 12 | Jun 11, 2026 | clinicaltrials |
| NCT03194893 | A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer | completed | Phase 3 | 50 | Hoffmann-La RocheINDUSTRY | 9 | Jun 11, 2026 | clinicaltrials |
| NCT04607421 | A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer | active not recruiting | Phase 3 | 841 | PfizerINDUSTRY | 29 | Jun 11, 2026 | clinicaltrials |
| NCT03301220 | A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma | completed | Phase 3 | 390 | Janssen Research & Development, LLCINDUSTRY | 24 | Jun 8, 2026 | clinicaltrials |
| NCT03516981 | A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495) | completed | Phase 2 | 245 | Merck Sharp & Dohme LLCINDUSTRY | 16 | Jun 8, 2026 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials